393 related articles for article (PubMed ID: 29902612)
21. Growing Role of Regorafenib in the Treatment of Patients with Sarcoma.
Agulnik M; Attia S
Target Oncol; 2018 Aug; 13(4):417-422. PubMed ID: 29931504
[TBL] [Abstract][Full Text] [Related]
22. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
Agulnik M; Costa RLB; Milhem M; Rademaker AW; Prunder BC; Daniels D; Rhodes BT; Humphreys C; Abbinanti S; Nye L; Cehic R; Polish A; Vintilescu C; McFarland T; Skubitz K; Robinson S; Okuno S; Van Tine BA
Ann Oncol; 2017 Jan; 28(1):121-127. PubMed ID: 27771610
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Duffaud F; Blay JY; Le Cesne A; Chevreau C; Boudou-Rouquette P; Kalbacher E; Penel N; Perrin C; Laurence V; Bompas E; Saada-Bouzid E; Delcambre C; Bertucci F; Cancel M; Schiffler C; Monard L; Bouvier C; Vidal V; Gaspar N; Chabaud S
Br J Cancer; 2023 Dec; 129(12):1940-1948. PubMed ID: 37914801
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
Le Cesne A; Chevreau C; Perrin C; Italiano A; Hervieu A; Blay JY; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Firmin N; Kalbacher E; Narciso B; Schiffler C; Yara S; Jimenez M; Bouvier C; Vidal V; Chabaud S; Duffaud F
ESMO Open; 2023 Jun; 8(3):101569. PubMed ID: 37285716
[TBL] [Abstract][Full Text] [Related]
28. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
Yoshino T; Komatsu Y; Yamada Y; Yamazaki K; Tsuji A; Ura T; Grothey A; Van Cutsem E; Wagner A; Cihon F; Hamada Y; Ohtsu A
Invest New Drugs; 2015 Jun; 33(3):740-50. PubMed ID: 25213161
[TBL] [Abstract][Full Text] [Related]
31. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
Tamoschus D; Draexler K; Chang J; Ngai C; Madin-Warburton M; Pitcher A
Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439
[TBL] [Abstract][Full Text] [Related]
33. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
34. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
37. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
Kim RD; Sanoff HK; Poklepovic AS; Soares H; Kim J; Lyu J; Liu Y; Nixon AB; Kim DW
Cancer; 2020 Aug; 126(15):3464-3470. PubMed ID: 32453456
[TBL] [Abstract][Full Text] [Related]
38. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.
Cicero G; De Luca R; Dieli F
Oncology; 2017; 93(6):354-358. PubMed ID: 28873372
[TBL] [Abstract][Full Text] [Related]
40. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
